Kalbitor ecallantide: Phase II started

Dyax began a double-blind, placebo-controlled, U.S. Phase II trial to compare 10, 30 and 60 mg subcutaneous Kalbitor in combination with conventional therapy vs. conventional therapy alone in 176 pati...